City Therapeutics' IPO

Q: When does the lock-up end?

City Therapeutics' IPO lock-up ends Apr 13, 2027. Its final prospectus says: “.”

Listed Oct 16, 2026 at $18 on Nasdaq as CTY.

Offer price

$18

Market cap

$931M

11,111,111

Today 16% above its $18 offer price; its first day closed +24.4%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See CTY ranked, live

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Oct 16, 2026.

What does City Therapeutics do?

“We are a clinical-stage biotechnology company developing the next generation of RNA interference ("RNAi") therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need.”

From its final prospectus (424B4), filed Oct 16, 2026

City Therapeutics' facts, each with its source
Fact	City Therapeutics
Incorporated	Delaware, 2023From its final prospectus (424B4) of Oct 16, 2026
Headquarters	Cambridge, MassachusettsFrom its final prospectus (424B4) of Oct 16, 2026
Employees	81 full-time, as of September 1, 2026From its final prospectus (424B4) of Oct 16, 2026
Website	citytx.comFrom its final prospectus (424B4) of Oct 16, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

City Therapeutics' facts, each with its source
Fact	City Therapeutics
Shares offered	11,111,111From the final prospectus (424B4) filed Oct 16, 2026
Offer price	$18 a shareFrom the final prospectus (424B4) filed Oct 16, 2026
Raised at that price	$200 millionFrom the final prospectus (424B4) filed Oct 16, 2026
Underwriters' discount	$14 millionFrom the final prospectus (424B4) filed Oct 16, 2026
Underwriters' option	1,666,666 more sharesFrom the final prospectus (424B4) filed Oct 16, 2026
Underwriters	Goldman Sachs, Jefferies, Stifel, and OppenheimerFrom the final prospectus (424B4) filed Oct 16, 2026, as its cover names them
Exchange	Nasdaq Global Market, as CTYFrom the final prospectus (424B4) filed Oct 16, 2026
Shares outstanding after	51,721,168From the final prospectus (424B4) filed Oct 16, 2026
Market cap at the offer price	$931 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

City Therapeutics' facts, each with its source
Fact	City Therapeutics
Collaboration revenue	$13.6 million, year to December 31, 2025From its final prospectus (424B4) of Oct 16, 2026, its summary financial data
Net loss	$58.5 million, year to December 31, 2025From its final prospectus (424B4) of Oct 16, 2026, its summary financial data
Cash	$172 million, as of June 30, 2026From its final prospectus (424B4) of Oct 16, 2026: cash, cash equivalents, and restricted cash
Last preferred stock	Series B preferredFrom its final prospectus (424B4) of Oct 16, 2026

What risks does City Therapeutics name first?

“We are a clinical-stage biotechnology company with a limited operating history and no products approved by regulators for commercial sale, which may make it difficult to evaluate our current and future business prospects.”
“The approach we are taking to discover and develop certain of our product candidates is novel and may never lead to marketable products.”
“We are early in our development efforts.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of City Therapeutics' IPO

City Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Sep 24, 2026	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Oct 13, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Oct 15, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed Oct 16, SEC EDGAR	Oct 15, 2026	final prospectus (424B4), filed Oct 16, SEC EDGAR
First tradeMassive's IPO calendar	Oct 16, 2026	Massive's IPO calendar
Lock-up endsfinal prospectus, SEC EDGAR: “”	Apr 13, 2027	final prospectus, SEC EDGAR: “”

How did its first days trade?

From its daily bars, each close against its $18 offer price.

City Therapeutics' first sessions
Day	Open	Close	From the offer
Oct 16	$23	$22.40	+24.4%
Oct 19	$21.94	$21.46	+19.2%
Oct 20	$21.44	$20.83	+15.7%
Oct 21	$20.78	$20.43	+13.5%
Oct 22	$20.41	$20.77	+15.4%

What is City Therapeutics' Quality Score?

New listing

7 trading days so far; 11 of the 14 checks wait for more history.

CTY's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

City Therapeutics IPO questions

When is City Therapeutics' IPO?

Listed Oct 16, 2026 at $18 on Nasdaq as CTY.

What is City Therapeutics' IPO price?

City Therapeutics' IPO priced at $18 a share, per its final prospectus of Oct 16, 2026.

How many shares is City Therapeutics selling?

11,111,111 shares, and the underwriters may buy 1,666,666 more, per its final prospectus (424B4).

Who are the underwriters?

Goldman Sachs, Jefferies, Stifel, and Oppenheimer, as the prospectus's cover names them.

When does the lock-up end?

City Therapeutics' IPO lock-⁠up ends Apr 13, 2027. Its final prospectus says: “.”

Does Breakaway rate City Therapeutics?

City Therapeutics has a Quality Score of 2 today, marked New listing for its first 21 sessions. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where City Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and October 2026's listings.